Prediction of homologous recombination deficiency from Oncomine Comprehensive Assay Plus correlating with SOPHiA DDM HRD Solution

• DOI: 10.1371/journal.pone.0298128
• Publication Date: 2024-03-25T17:35:48Z
• Authors: Jun Kang; Kiyong Na; Haeyoun Kang; Uiju Cho; Sun Young Kwon; Sohyun Hwang; Ahwon Lee
• Keywords: Microsatellite Instability

Objective Poly(ADP-ribose) polymerase (PARP) inhibitors are used for targeted therapy ovarian cancer with homologous recombination deficiency (HRD). In this study, we aimed to develop a prediction model predict the genomic integrity (GI) index of SOPHiA DDM HRD Solution from Oncomine Comprehensive Assay (OCA) Plus. We also tried find cut-off value instability metric (GIM) OCA Plus that correlates GI Solution. Methods included 87 cases high-grade serous carcinoma five tertiary referral hospitals in Republic Korea. developed an As predictor variables model, score, which percent loss heterozygosity (%LOH), telomeric allelic imbalance (%TAI), large-scale state transitions (%LST), and (GIM). To build employed penalized logistic regression technique. Results The final equation is -21.77 + 0.200 × GIM 0.102 %LOH 0.037 %TAI 0.261 %LST. improve performance added borderline result category results. accuracy our status was 0.958 test set. using 16 0.911. Conclusion provides reliable biomarker deficiency.